CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical trial for various solid tumors.
CAN2109 is a novel long-acting Immunogenic cell death (ICD) inducer, which acts as a bi-functional immune modulator to kill tumor cells while preserving tumor antigens for efficient cross-priming of tumor-specific T cells. CAN2109 not only possesses direct tumor cell killings, but also induces strong cell-mediated immune responses including both CD4+ and CD8+ T cells activation. In addition, CAN2109 synergizes with checkpoint inhibitors to induce systemic immunity with regression of local and distant tumors.